Austrian Biotech Plans Zika Vaccine Clinical Trials in 12 Months
Wednesday, July 13, 2016
Themis Bioscience has signed a license deal with the French research institute giving it extensive rights to the Zika vaccine candidate, which is based on established measles vaccine technology.
More than a dozen small biotech firms and other organizations are working on vaccines against mosquito-borne Zika, which has been linked to birth defects and neurological disorders, although most work is at a very early stage.
Erich Tauber, chief executive of Themis, believes his company’s project will benefit from the proven track record behind the technology used to immunize against measles.
- Health Care